

References

1. NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines ([HERE](#))
2. FDA. PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers ([HERE](#))
3. Pfizer Laboratories Div Pfizer Inc. PAXLOVID- nirmatrelvir and ritonavir. Full Prescribing Information. ([HERE](#))
4. CDC. COVID-19 Treatments and Medications ([HERE](#))
5. FDA. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid. ([HERE](#))
6. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *N Engl J Med*. 2022 Apr 14;386(15):1397-1408.. ([HERE](#))
7. EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 ([HERE](#))
8. Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). ([HERE](#))
9. Aggarwal NR, Molina KC, Beaty LE, et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. *Lancet Infect Dis*. 2023 Jun;23(6):696-705. ([HERE](#))
10. National Bureau of Health Statistics. New Report Confirms U.S. Life Expectancy has Declined to Lowest Level Since 1996. ([HERE](#))
11. Shiels MS, Haque AT, de González AB, et al. Leading Causes of Death in the US During the COVID-19 Pandemic, March 2020 to October 2021. *JAMA Internal Medicine* 2021 July 5. DOI: 10.1001/jamainternmed.2022.2476. ([HERE](#))
12. The COVID States Project ([HERE](#))
13. Medscape. Medscape survey finds reasons Paxlovid is underprescribed for those 65 and older despite its effectiveness against COVID complications. *Non-peer reviewed convenience survey*. ([HERE](#))
14. FDA. Meeting of the Antimicrobial Drugs Advisory Committee – March 16th 2023. ([HERE](#))